Loading stock data…
HUMA
$1.33-0.06 (-4.32%)
Market OpenUpdated 1:31 PM EDT
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Humacyte, Inc. in the Healthcare sector is trading at $1.33. Wall Street consensus targets $1.90 (5 analysts), implying a +42.9% move over the next 12 months. The stock is currently 53% below its 52-week high of $2.84, remaining 9.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +42.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $495,000↑ | $467,000↓ | $753,000↑ | $301,000↓ | $517,000 |
| Gross Profit | -$1.54M↑ | -$8.62M↓ | $493,000↑ | $88,000↓ | $370,000 |
| Operating Income | -$28.93M↑ | -$30.84M↓ | -$24.39M↑ | -$29.73M↓ | -$23.18M |
| Net Income | -$17.62M↑ | -$24.80M↓ | -$17.51M↑ | -$37.66M↓ | $39.14M |
Peer Comparison
JNJUNHPFE
Fundamentals
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-839.56%
Volume
Today's trading volume
4.06M
Recent News
Humacyte (HUMA) Q1 2025 Earnings Transcript
Laura Niklason: Thank you, Tom and good morning, everyone and thank you for joining us for our first quarter 2025 financial results and business update call. Following the landmark success of obtaining FDA approval of Symvess for the treatment of extremity vascular trauma late last year, we're keenly focused on the commercial launch of this groundbreaking product. Supporting the launch is our number one priority and we're pleased by the traction gained in our interactions with hospitals despite the current volatile economic environment.
Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis Data - Has The Bull Case Changed?
Humacyte recently reported research showing its acellular tissue engineered vessel (ATEV) used for dialysis access can self-repair after repeated needle cannulation, maintaining structural integrity and showing tissue regeneration and infection resistance in explants followed for up to 5.5 years. Alongside this long-term self-repair evidence, Humacyte is preparing to share interim Phase 3 dialysis data in June 2026 and is expanding Symvess access across the U.S. Department of Veterans...
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Humacyte, Inc. (NASDAQ:HUMA) is among the best penny stocks under $1 according to hedge funds. TheFly reported on May 14 that HUMA saw its price target increased at TD Cowen to $1.50 from $1.00 in a revised research update, with […]
Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ...
Humacyte Inc (HUMA) reports significant sales growth and international expansion efforts, despite facing increased losses and restructuring challenges in Q1 2026.
Humacyte (HUMA) Q1 2026 Earnings Transcript
Laura Niklason: Thank you, Tom, and good morning, everyone, and thank you for joining us for our first quarter financial results and business update call for 2026. To remind this audience, Humacyte's key corporate goals for this year include advancing the U.S. and global commercial launch of Symvess, completion of the V012 Phase III pivotal trial of our ATEV in dialysis access, the planned filing of a supplemental BLA with the FDA in the dialysis indication and the commencement of a human study of our coronary tissue engineered vessel or CTEV in coronary artery bypass grafting. During our first quarter and in recent weeks, we continue to make progress in our U.S. market launch of Symvess as well as expand commercialization into international markets.